文献速递妇科

普萘洛尔联合化疗用于上皮性卵巢癌患者的前瞻性先导试验及循环免疫细胞基因表达评估

Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
PubMed 文献 · Gynecol Oncol · 2019-07-25

该前瞻性先导试验评估新诊断II-IV期上皮性卵巢癌患者在初始治疗全程接受普萘洛尔β-肾上腺素能阻断的可行性。32例入组,26例可评估,18例(69%,90%可信区间53-81%)完成6个化疗周期联合普萘洛尔。完成治疗后生活质量、焦虑和抑郁改善,白细胞促炎基因表达下降。

要点

  • 26例可评估患者中18例(69%)完成6个化疗周期联合普萘洛尔,90%可信区间53-81%。
  • 23例有基线和6个月随访数据的患者中,总体生活质量、焦虑和抑郁改善(P<0.05)。
  • 完成治疗后白细胞促炎基因表达下降(P=0.03),血清IL-6和IL-8下降先于化疗反应(P<0.0014)。

核心结论

  • 在新诊断II-IV期上皮性卵巢癌初始治疗期间使用普萘洛尔是可行的,且治疗导致肾上腺素能应激反应标志物下降。
  • 普萘洛尔联合化疗可能使生活质量较基线改善。

研究设计与样本

  • 前瞻性先导试验,纳入新诊断II-IV期上皮性卵巢癌女性,在开始化疗或手术前启动普萘洛尔。
  • 32例入组,3例因从未服用普萘洛尔被排除,另3例不符合纳入标准,最终26例可评估;中位年龄59.9岁,88.5%为IIIC/IV期,38.5%接受初次减瘤术。
  • 可行性定义为能够在肾上腺素能抑制下完成6个化疗周期的患者比例;采用描述性统计总结调查问卷,配对变化用符号秩检验分析,随机截距Tobit模型检查免疫反应。

主要发现

  • 26例可评估患者中18例(69%)完成6个化疗周期联合普萘洛尔,90%可信区间53-81%(真实成功比例≥60%的后验概率为82%)。
  • 23例有基线和6个月随访数据的患者中,完成治疗后总体生活质量、焦虑和抑郁改善(P<0.05),白细胞促炎基因表达下降(P=0.03)。
  • 血清IL-6和IL-8较基线下降先于化疗反应(P<0.0014);IL-10较基线变化先于完全缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the feasibility of pharmacologic beta-adrenergic blockade in women with newly diagnosed stage II-IV epithelial ovarian cancer (EOC) throughout primary treatment. METHODS: Patients initiated propranolol prior to beginning chemotherapy or surgery. Feasibility was assessed as proportion able to complete 6 chemotherapy cycles while on adrenergic suppression. Descriptive statistics summarized surveys, and paired changes were analyzed using signed rank tests. Random-intercept Tobit models examined immune response. RESULTS: Median age was 59.9; 88.5% were stage IIIC/IV; and 38.5% underwent primary debulking. Thirty-two patients were enrolled; 3 excluded because they never took propranolol; an additional 3 didn't meet inclusion criteria, leaving 26 evaluable. Eighteen of 26 (69%), 90% credible interval (CI) of 53-81%, completed 6 chemotherapy cycles plus propranolol (an 82% posterior probability that the true proportion of success is ≥60%). Among the 23 patients with baseline and six month follow up data, overall QOL, anxiety, and depression improved (P < 0.05) and leukocyte expression of pro-inflammatory genes declined (P = 0.03) after completion of therapy. Decrease from baseline of serum IL-6 and IL-8 preceded response to chemotherapy (P < 0.0014). Change from baseline IL-10 preceded complete response. CONCLUSION: Use of propranolol during primary treatment of EOC is feasible and treatment resulted in decrease in markers of adrenergic stress response. In combination with chemotherapy, propranolol potentially results in improved QOL over baseline.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ramondetta LM, Hu W, Thaker PH, et al. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019. PMID: 31353053. doi:10.1016/j.ygyno.2019.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。